RANCHO CORDOVA, Calif.,
June 5, 2019 /PRNewswire/ --
ThermoGenesis Corp., a wholly owned subsidiary of Cesca
Therapeutics (Nasdaq: KOOL), and a market leader in automated
cellular processing, today announced that it will participate in
and exhibit its novel PXP® System, for point-of-care preparation of
bone marrow concentrate (BMC), at The Orthobiologic Institute's
(TOBI) 10th Annual PRP & Regenerative Medicine Symposium,
Workshops & Cadaver Labs. The company is a Bronze sponsor
of this year's symposium, being held June
6-8 at McCormick Place in Chicago. Activities include:
- June 6: 8:00 a.m. - 12:00 p.m. CDT ThermoGenesis will
participate in the Lipoaspirate, Bone Marrow Aspirate &
Intraosseous Injections Workshop, intended to illustrate basic
science and techniques to implement cutting-edge treatments in
orthopedic practice, including bone marrow aspiration and
processing kits.
-
- During the workshop, ThermoGenesis representatives will assist
faculty to highlight the contents of the PXP® System,
discuss the features of processing and review similarities and
differences of currently marketed, automated cell processing
products.
- June 6: 1:00 p.m. - 5:00
p.m. CDT ThermoGenesis will participate in Hands-On
Cadaver Labs: Lipoaspirate, Bone Marrow Aspirate & Intraosseous
Injections, which will give attendees direct experience with
biologic treatments, as taught by field experts.
-
- During the lab, ThermoGenesis will showcase how the
PXP® System functions and will be available to answer
technical questions.
- June 6: 5:00 pm – 6:00 pm
CDT ThermoGenesis is co-sponsoring the OrthoHealing
Method (OHM) reception which will feature an introduction to an OHM
certified network of providers and internationally recognized
doctors, experts in the field of Orthopaedics, Sports Medicine and
Regenerative Medicine.
- June 7-8: 8:00 –
5:30 pm CDT ThermoGenesis will
host Booth #609, exhibiting the PXP® System and its
benefits for use by orthopedic physicians.
Haihong Zhu, President of
ThermoGenesis, stated, "We are delighted to once again participate
in the annual TOBI PRP & Regenerative Medicine Symposium, this
time, as a Bronze sponsor, and to exhibit and demonstrate the newly
launched PXP® System. The PXP® negates
many of the inadequacies of currently available systems, including
red blood cell contamination in the resulting cell concentrate
which can diminish the efficacy of cell-based treatments. By
contrast, the automated, closed PXP® System allows
clinicians to rapidly (in under 20 minutes) achieve very high stem
cell recovery with negligible RBC and granulocyte
contamination. As such, it is expected to bring significant
benefits to today's orthopedic market."
About the PXP® System
The
PXP® laboratory equipment allows for the rapid,
automated processing of autologous bone marrow-derived stem cells
at the point of care, such as in surgical centers and
clinics. It affords:
- consistently high recovery of MSCs and HSCs
- greater than 99% RBC depletion
- automation of the volume reduction process
- simultaneous processing of multiple bone marrow samples,
and
- processing of bone marrow without cell separation media or a
sedimentation agent.
About TOBI 2019
The Orthobiologic Institute's PRP
& Regenerative Medicine Symposium is an annual gathering of
more than 500 clinicians, researchers, and industry professionals
from across the globe seeking to learn about cutting-edge research
and best practices in orthobiologic regenerative medicine.
About ThermoGenesis
ThermoGenesis develops,
commercializes and markets a full suite of solutions for automated
clinical biobanking, point-of-care applications, and automation for
immuno-oncology. The Company has developed an automated,
functionally closed CAR-TXpress™ Platform to
streamline the manufacturing process for the emerging CAR-T
immunotherapy market. For additional information, please visit:
www.thermogenesis.com.
About Cesca Therapeutics Inc.
Cesca Therapeutics
Inc. is a market leader in cell processing technologies and
autologous cell therapies for regenerative medicine. For more
information, visit: www.cescatherapeutics.com.
Forward-Looking Statement
The statements contained
herein may include statements of future expectations and other
forward-looking statements that are based on management's current
views and assumptions and involve known and unknown risks and
uncertainties that could cause actual results, performance or
events to differ materially from those expressed or implied in
such statements. A more complete description of risks that could
cause actual events to differ from the outcomes predicted by Cesca
Therapeutics' forward-looking statements is set forth under the
caption "Risk Factors" in Cesca Therapeutics' Annual Report on Form
10-K and other reports it files with the Securities and Exchange
Commission from time to time, and you should consider each of those
factors when evaluating the forward-looking statements.
Company Contact:
Wendy
Samford
916-858-5191
ir@thermogenesis.com
Investor Contact:
Paula
Schwartz, Rx Communications
917-322-2216
pschwartz@rxir.com
View original
content:http://www.prnewswire.com/news-releases/thermogenesis-to-participate-in-the-orthobiologic-institutes-10th-annual-prp--regenerative-medicine-symposium-300862229.html
SOURCE Cesca Therapeutics